Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STAT5b shRNA is a research-grade gene-silencing tool designed to knock down the expression of the Signal Transducer and Activator of Transcription 5b (STAT5b) gene. STAT5b is a transcription factor implicated in cancer cell proliferation, chemoresistance, and invasion, particularly in pancreatic cancer and glioblastoma. By utilizing the RNA interference (RNAi) pathway, this short hairpin RNA (shRNA) construct, typically delivered via lentiviral or plasmid vectors, reduces STAT5b protein levels. In preclinical studies, suppression of STAT5b has been shown to inhibit tumor growth, impair cancer cell motility, and sensitize cells to chemotherapeutic agents like gemcitabine. It is primarily used as a laboratory tool to validate STAT5b as a therapeutic target and is commercially available for non-commercial research use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on STAT5b shRNA.